Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement...
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: ...
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications NEW YORK, 12 juin...
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia NEW YORK...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.